Dexmedetomidine may upregulate the expression of caveolin-1 in lung tissues of rats with sepsis and improve the short-term outcome

• Published in: Molecular medicine reports Vol. 15; no. 2; pp. 635 - 642
• Main Authors: Zhang, Yun, Ran, Ke, Zhang, Shu-Bin, Jiang, Lili, Wang, Dan, Li, Zhi-Jian
• Format: Journal Article
• Language: English
• Published: Greece D.A. Spandidos 01.02.2017; Spandidos Publications; Spandidos Publications UK Ltd
• Subjects: Abdomen; Adrenergic alpha-2 Receptor Antagonists - pharmacology; Adrenergic alpha-2 Receptor Antagonists - therapeutic use; Adrenergic receptors; Animals; Blood Gas Analysis; Body temperature; Body Temperature - drug effects; Care and treatment; Caveolin; Caveolin 1 - genetics; Caveolin 1 - metabolism; Caveolin-1; Caveolins; Cecum; Dexmedetomidine; Dexmedetomidine - pharmacology; Disease Models, Animal; Endocytosis; FDA approval; Hospitals; Hypnotics and Sedatives - pharmacology; Imidazoles; Imidazoles - pharmacology; Imidazoles - therapeutic use; Imidazoline; Inflammation; Kinases; Laboratories; Lactic acid; Lung - metabolism; Lung - pathology; Macrophages; Male; Metabolic pathways; Nitric oxide; Phosphorylation; Proteins; Rats; Rats, Sprague-Dawley; Rodents; secondary lung injury; Sepsis; Sepsis - drug therapy; Sepsis - mortality; Sepsis - pathology; signaling crosstalk; Studies; Surgery; TLR4 protein; Toll-Like Receptor 4 - metabolism; Toll-like receptors; Up-Regulation - drug effects; United States > US; China

Dexmedetomidine (DXM) is a selective α2-adrenoceptor (α2-AR) and imidazoline receptor (IR) agonist that has been reported to regulate inflammatory responses mediated by diverse signaling pathways through α2-AR. The majority of the reported receptors or downstream molecules have been demonstrated to...